The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Primary prevention of cardiovascular disease: A review of contemporary guidance and literature
Open accessAbstract
Cardiovascular disease is a significant and ever-growing problem in the United Kingdom, accounting for nearly one-third of all deaths and leading to significant morbidity. It is also of particular and pressing interest as developing countries experience a change in lifestyle which introduces novel risk factors for cardiovascular disease, leading to a boom in cardiovascular disease risk throughout the developing world. The burden of cardiovascular disease can be ameliorated by careful risk reduction and, as such, primary prevention is an important priority for all developers of health policy. Strong consensus exists between international guidelines regarding the necessity of smoking cessation, weight optimisation and the importance of exercise, whilst guidelines vary slightly in their approach to hypertension and considerably regarding their approach to optimal lipid profile which remains a contentious issue. Previously fashionable ideas such as the polypill appear devoid of in-vivo efficacy, but there remain areas of future interest such as the benefit of serum urate reduction and utility of reduction of homocysteine levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“In DM serum glucose reduction is shown to reduce CVD, with lowest risk at normal blood sugars.(54) More intense glucose reductions were deleterious, with particular CVD risk from certain thiazolidinediones and dipeptidyl peptidase-4 inhibitors.”
BackgroundEuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
MACMAHON, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90878-9 · Cited by 4,253 · cited 1×
“Previous meta-analyses have shown a reduction in CVD risk over a wider range of BPs suggesting that there is no lower limit to the benefit of BP reduction, and no obvious cut-off at which further reductions become harmful.(41,42) Contemporary meta-analyses indicate that the benefits of lowering BP from a baseline< 140…”
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
Roth, G. A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S. F., Abyu, G., Ahmed, M., Aksut, B., Alam, T., Alam, K., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.052 · Cited by 3,791
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015
Forouzanfar, M. H., Liu, P., Roth, G. A., Ng, M., Biryukov, S., Marczak, L., Alexander, L., Estep, K., Hassen Abate, K., Akinyemiju, T. F., et al. (2017) · JAMA · doi:10.1001/jama.2016.19043 · Cited by 2,381
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Miller, N. H., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437740.48606.d1 · Cited by 2,261
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017) · BMJ · doi:10.1136/bmj.j2099 · Cited by 1,703
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Body Fat Distribution and Risk of Cardiovascular Disease: An Update
Després, J.-P. (2012) · Circulation · doi:10.1161/circulationaha.111.067264 · Cited by 1,481
de Souza, R. J., Mente, A., Maroleanu, A., Cozma, A. I., Ha, V., Kishibe, T., Uleryk, E., Budylowski, P., Schünemann, H., Beyene, J., et al. (2015) · BMJ · doi:10.1136/bmj.h3978 · Cited by 1,424
European Society of hypertension position paper on ambulatory blood pressure monitoring
O’Brien, E., Parati, G., Stergiou, G., Asmar, R., Beilin, L., Bilo, G., Clement, D., de la Sierra, A., de Leeuw, P., Dolan, E., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328363e964 · Cited by 1,419
Cook, N. R., Cutler, J. A., Obarzanek, E., Buring, J. E., Rexrode, K. M., Kumanyika, S. K., Appel, L. J., & Whelton, P. K. (2007) · BMJ · doi:10.1136/bmj.39147.604896.55 · Cited by 1,179 · cited 1×
“The reverse is also true: studies looking at reduction in salt intake show consistent reductions in BP, particularly in hypertensive individuals,(50) and there is evidence of CVD event reduction.(51) Given the above, all three guidelines recommend reduction in salt intake on an individual and population level regardle…”
BackgroundAnthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk
Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Houston Miller, N., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.003 · Cited by 1,160
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Dose Response Between Physical Activity and Risk of Coronary Heart Disease: A Meta-Analysis
Sattelmair, J., Pertman, J., Ding, E. L., Kohl, H. W., Haskell, W., & Lee, I.-M. (2011) · Circulation · doi:10.1161/circulationaha.110.010710 · Cited by 1,052
Role of homocysteine in the development of cardiovascular disease
Ganguly, P., & Alam, S. F. (2015) · Nutrition Journal · doi:10.1186/1475-2891-14-6 · Cited by 1,028
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring
Parati, G., Stergiou, G., O’Brien, E., Asmar, R., Beilin, L., Bilo, G., Clement, D., de la Sierra, A., de Leeuw, P., Dolan, E., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000221 · Cited by 1,021
Smoking cessation guidelines for health professionals: an update
West, R. (2000) · Thorax · doi:10.1136/thorax.55.12.987 · Cited by 982
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.038 · Cited by 938
Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., Howard, G., Pearson, T. A., Rothwell, P. M., Ruilope, L. M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31924-x · Cited by 883
Cardiovascular Effects and Benefits of Exercise
Nystoriak, M. A., & Bhatnagar, A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00135 · Cited by 833
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Bundy, J. D., Li, C., Stuchlik, P., Bu, X., Kelly, T. N., Mills, K. T., He, H., Chen, J., Whelton, P. K., & He, J. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1421 · Cited by 783
Dickinson, H. O., Mason, J. M., Nicolson, D. J., Campbell, F., Beyer, F. R., Cook, J. V., Williams, B., & Ford, G. A. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000199800.72563.26 · Cited by 759
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
Kottke, T. E. (1988) · JAMA · doi:10.1001/jama.259.19.2883 · Cited by 741
Unal, B., Critchley, J. A., & Capewell, S. (2004) · Circulation · doi:10.1161/01.cir.0000118498.35499.b2 · Cited by 739
Association of animal and plant protein intake with all-cause and cause-specific mortality.
Song, M., Fung, T. T., Hu, F. B., Willett, W. C., Longo, V. D., Chan, A. T., & Giovannucci, E. L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.4182 · Cited by 735
The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes
King, P., Peacock, I., & Donnelly, R. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00092.x · Cited by 695
Ruegsegger, G. N., & Booth, F. W. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029694 · Cited by 690
Holmes, M. V., Dale, C. E., Zuccolo, L., Silverwood, R. J., Guo, Y., Ye, Z., Prieto-Merino, D., Dehghan, A., Trompet, S., Wong, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4164 · Cited by 669 · cited 2×
“A recent large mendelian analysis by Holmes et al.(32) has, however, shown that within a genetic subset for alcohol dehydrogenase, reductions in alcohol intake are associated with reduction in CVD risk across the spectrum of alcohol intake.”
Blood pressure and cardiovascular disease in the Asia Pacific region
(2003) · Journal of Hypertension · doi:10.1097/00004872-200304000-00013 · Cited by 644
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Lonn, E. M., Bosch, J., López-Jaramillo, P., Zhu, J., Liu, L., Pais, P., Diaz, R., Xavier, D., Sliwa, K., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600175 · Cited by 618
Sports-Related Sudden Death in the General Population
Marijon, E., Tafflet, M., Celermajer, D. S., Dumas, F., Perier, M.-C., Mustafic, H., Toussaint, J.-F., Desnos, M., Rieu, M., Benameur, N., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.008979 · Cited by 543
Ockene, I. S., & Miller, N. H. (1997) · Circulation · doi:10.1161/01.cir.96.9.3243 · Cited by 541
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub5 · Cited by 474
Brunström, M., & Carlberg, B. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6015 · Cited by 471
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers
Klatsky, A. L., Armstrong, M. A., & Friedman, G. D. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)91107-h · Cited by 360
The Effectiveness of the Nicotine Patch for Smoking Cessation: A Meta-analysis
Fiore, M. C. (1994) · JAMA · doi:10.1001/jama.1994.03510480064036 · Cited by 345
Bell, S., Daskalopoulou, M., Rapsomaniki, E., George, J., Britton, A., Bobak, M., Casas, J. P., Dale, C. E., Denaxas, S., Shah, A. D., et al. (2017) · BMJ · doi:10.1136/bmj.j909 · Cited by 332
Eijsvogels, T. M. H., Molossi, S., Lee, D.-C., Emery, M. S., & Thompson, P. D. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.034 · Cited by 305
Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A. S., & On behalf of the Guideline Development Group (2014) · BMJ · doi:10.1136/bmj.g4356 · Cited by 292
Koskinas, K. C., Siontis, G. C. M., Piccolo, R., Mavridis, D., Räber, L., Mach, F., & Windecker, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx566 · Cited by 252
Ramos, R., Comas-Cufí, M., Martí-Lluch, R., Balló, E., Ponjoan, A., Alves-Cabratosa, L., Blanch, J., Marrugat, J., Elosua, R., Grau, M., et al. (2018) · BMJ · doi:10.1136/bmj.k3359 · Cited by 215
The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.
Fiore, M. C., Smith, S. S., Jorenby, D. E., & Baker, T. B. (1994) · PubMed · Cited by 214
Should people at low risk of cardiovascular disease take a statin?
Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2013) · BMJ · doi:10.1136/bmj.f6123 · Cited by 208
Individual Blood Pressure Responses to Changes in Salt Intake: Results From the DASH-Sodium Trial
Obarzanek, E., Proschan, M. A., Vollmer, W. M., Moore, T. J., Sacks, F. M., Appel, L. J., Svetkey, L. P., Most-Windhauser, M. M., & Cutler, J. A. (2003) · Hypertension · doi:10.1161/01.hyp.0000091267.39066.72 · Cited by 198
Kottke, T. E. (1988) · JAMA · doi:10.1001/jama.1988.03720190050031 · Cited by 193
Abdominal Adiposity and Cardiometabolic Risk: Do We Have All the Answers?
Haffner, S. M. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.006 · Cited by 188
Associations of resistance exercise with cardiovascular disease morbidity and mortality
LIU, Y., LEE, D.-C., LI, Y., ZHU, W., ZHANG, R., SUI, X., LAVIE, C. J., & BLAIR, S. N. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001822 · Cited by 187
Contemporary model for cardiovascular risk prediction in people with type 2 diabetes
Kengne, A. P., Patel, A., Marre, M., Travert, F., Lievre, M., Zoungas, S., Chalmers, J., Colagiuri, S., Grobbee, D. E., Hamet, P., et al. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826710394270 · Cited by 183
Sympathomimetic Effects of Acute E‐Cigarette Use: Role of Nicotine and Non‐Nicotine Constituents
Moheimani, R. S., Bhetraratana, M., Peters, K. M., Yang, B. K., Yin, F., GORNBEIN, J. A., Araujo, J. A., & Middlekauff, H. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006579 · Cited by 183
Han, B. H., Sutin, D., Williamson, J. D., Davis, B. R., Piller, L. B., Pervin, H., Pressel, S. L., Blaum, C. S., & for the ALLHAT Collaborative Research Group (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1442 · Cited by 177
Effects on cardiovascular risk factors of weight losses limited to 5–10 %
Brown, J. D., Buscemi, J., Milsom, V. A., Malcolm, R. J., & O'Neil, P. M. (2015) · Translational Behavioral Medicine · doi:10.1007/s13142-015-0353-9 · Cited by 170
Vishram, J. K. K., Borglykke, A., Andreasen, A. H., Jeppesen, J., Ibsen, H., Jørgensen, T., Broda, G., Palmieri, L., Giampaoli, S., Donfrancesco, C., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.201400 · Cited by 167
Aspirin Therapy in Primary Cardiovascular Disease Prevention
Halvorsen, S., Andreotti, F., ten Berg, J. M., Cattaneo, M., Coccheri, S., Marchioli, R., Morais, J., Verheugt, F. W. A., & De Caterina, R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.049 · Cited by 166
van Dijk, S. B., Takken, T., Prinsen, E. C., & Wittink, H. M. (2012) · Netherlands Heart Journal · doi:10.1007/s12471-011-0237-7 · Cited by 164
Environmental tobacco smoke and ischemic heart disease
Law, M. R., & Wald, N. J. (2003) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(03)00078-1 · Cited by 161
Shields, P. G., Berman, M. L., Brasky, T. M., Freudenheim, J. L., Mathé, E. A., McElroy, J. P., Song, M., & Wewers, M. D. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0358 · Cited by 156
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001547 · Cited by 152
Dorresteijn, J. A. N., van der Graaf, Y., Spiering, W., Grobbee, D. E., Bots, M. L., & Visseren, F. L. J. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.179143 · Cited by 150
Leong, D. P., Smyth, A., Teo, K. K., McKee, M., Rangarajan, S., Pais, P., Liu, L., Anand, S. S., & Yusuf, S. (2014) · Circulation · doi:10.1161/circulationaha.113.007627 · Cited by 141
Primary Prevention With Statin Therapy in the Elderly
Ridker, P. M., Lonn, E., Paynter, N. P., Glynn, R. J., & Yusuf, S. (2017) · Circulation · doi:10.1161/circulationaha.117.028271 · Cited by 140
Hom, S., Chen, L., Wang, T., Ghebrehiwet, B., Yin, W., & Rubenstein, D. A. (2016) · Platelets · doi:10.3109/09537104.2016.1158403 · Cited by 138
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 123
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Stoekenbroek, R. M., Kallend, D. G., Wijngaard, P. L. J., & Kastelein, J. J. P. (2018) · Future Cardiology · doi:10.2217/fca-2018-0067 · Cited by 115
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
Blood Pressure Parameters and Risk of Fatal Stroke, NHANES II Mortality Study
Brown, D. L., GILES, W., & Greenlund, K. J. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.08.004 · Cited by 97
Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet Function
Nocella, C., Biondi‐Zoccai, G., Sciarretta, S., Peruzzi, M., Pagano, F., Loffredo, L., Pignatelli, P., Bullen, C., Frati, G., & Carnevale, R. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.07.029 · Cited by 97
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 95
Genuth, S. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00005 · Cited by 92
Tzivoni, D., Keren, A., Meyler, S., Khoury, Z., Lerer, T., & Brunel, P. (1998) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007757530765 · Cited by 87
Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension
Sheppard, J. P., Stevens, S., Stevens, R., Martin, U., Mant, J., Hobbs, R. F., & McManus, R. J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.4684 · Cited by 86
Bhatnagar, A. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0505-6 · Cited by 85
Zanchetti, A., Liu, L., Mancia, G., Parati, G., Grassi, G. M., Stramba‐Badiale, M., Silani, V., Bilo, G., Corrao, G., Zambon, A., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000254 · Cited by 79
Prevention of cardiovascular disease in the elderly
Kannel, W. B., Doyle, J. T., Shephard, R. J., Stamler, J., & Vokonas, P. (1987) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(87)80443-6 · Cited by 63
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Management of hypertension in ethnic minorities
Khan, J., & Beevers, D. G. (2005) · Heart · doi:10.1136/hrt.2004.044560 · Cited by 60
Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease
Bowman, L., Hopewell, J. C., Chen, F., Wallendszus, K., & Stevens, W. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.11.029 · Cited by 56
Chen, J., Lan, J., Cheng, C., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141542 · Cited by 54
Salsali, A., Kim, G.-H., Woerle, H. J., Broedl, U. C., & Hantel, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12734 · Cited by 47
Alcohol and cardiovascular disease
Mukamal, K. J., & Lazo, M. (2017) · BMJ · doi:10.1136/bmj.j1340 · Cited by 47
Stam‐Slob, M. C., Visseren, F. L. J., Jukema, J. W., van der Graaf, Y., Poulter, N. R., Gupta, A. K., Sattar, N. A., Macfarlane, P. W., Kearney, P. M., de Craen, A. J. M., et al. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1023-8 · Cited by 41
Alcohol consumption over time and mortality in the Swedish Women’s Lifestyle and Health cohort
Licaj, I., Sandin, S., Skeie, G., Adami, H., Roswall, N., & Weiderpass, E. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012862 · Cited by 19
Khosravi, A., Tabib, A. A., Golshadi, I., Siadat, Z. D., Bahonar, A., Zarfeshani, S., Alikhasi, H., Rezaee, S., Noori, F., Jazi, M. H., et al. (2012) · PubMed Central · Cited by 16
Hughes, A. D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000079 · Cited by 1
Cited by
The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art
Esse, R., Barroso, M., Tavares de Almeida, I., & Castro, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040867 · Cited by 336
Khan, J., Deb, P. K., Priya, S., Medina, K. D., Devi, R., Walode, S. G., & Rudrapal, M. (2021) · Molecules · doi:10.3390/molecules26134021 · Cited by 334
Applications of Graphene Quantum Dots in Biomedical Sensors
Mansuriya, B., & Altintas, Z. (2020) · Sensors · doi:10.3390/s20041072 · Cited by 276
Wearable Photoplethysmography for Cardiovascular Monitoring
Charlton, P. H., Kyriacou, P. A., Mant, J., Marozas, V., Chowienczyk, P., & Alastruey, J. (2022) · Proceedings of the IEEE · doi:10.1109/jproc.2022.3149785 · Cited by 250
“Several effective strategies have been identified to reduce cardiovascular (CV) risk, including drugs, such as antihypertensives, lipid-lowering agents, and anticoagulants, and lifestyle changes, such as regular exercise, improved diet, and weight control [2].”
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Metadata
- Authors
- Stewart, J., Manmathan, G., & Wilkinson, P.
- Venue
- JRSM Cardiovascular Disease
- Publisher
- SAGE Publications
- Published
- 2017-01
- Volume
- 6
- Pages
- 2048004016687211-2048004016687211
- ISSN
- 2048-0040 (ISSN-L)
- OpenAlex
- W2574421857
- Cited by
- 464
- References
- 128
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.